Bausch Health Companies Inc. (BHC)
BHC Price and Sentiment
BHC Latest news
Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.
Bausch Health Companies Inc (NYSE: BHC) reported Q3 revenues of $2.111 billion, down 1% Y/Y, missing the consensus of $2.66 billion. Excluding the impact of foreign exchange, divestitures & discontinuations, revenue was flat organically.
Bausch Health Companies, Inc. (BHC) CEO Joe Papa on Q3 2021 Results - Earnings Call Transcript
Bausch (BHC) delivered earnings and revenue surprises of 6.54% and -1.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Bausch Health Cos. Inc. BHC, +1.60% gained 1.2% in premarket trading on Tuesday after the company said it plans to spin off its medical aesthetics business in the next three months.
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States2021-10-25 08:00
Salix Pharmaceuticals' First Liver Health Annual Trends Report Highlights Urgent Need for Evidence-Based Guidelines to be Adopted by Physicians LAVAL, Quebec, Oct. 25, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal and liver diseases, today released key findings from a survey of health care providers (HCP) treating chronic liver disease (CLD), including potential gaps in prevention and diagnosis efforts. The Liver Health Annual Trends Report, which surveyed 100 physicians active in the management and treatment of CLD, offers facts and trends about CLD in America, a disease that affects an estimated 4.5 million adults in the United States.1 Research indicates that more people aged 25-54 die from CLD and cirrhosis than diabetes or stroke.2 The results of this survey and in-d
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting2021-10-25 07:00
Research Findings for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) Will be Presented LAVAL, Quebec, Oct. 25, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the treatment of gastrointestinal (GI) diseases and conditions, today announced seven posters featuring new data for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) are being presented at the American College of Gastroenterology® (ACG) 2021 Annual Scientific Meeting, which is taking place Oct. 22-27, 2021 in Las Vegas. "Salix is pleased to present important new clinical data on three key products in our gastrointestinal portfolio at ACG's annual scientific meeting," said Robert Spurr, president, Salix Pharmaceuticals.
LAVAL, QC, Oct. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its third-quarter 2021 financial results on Tuesday, Nov. 2, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m.
Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.